Biophytis (EPA:ALBPS) | WebDisclosure

Basculer en Français

11295	Companies
250999	Keywords
179926	Articles
136864	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 02/25/2025 at 07:00, 1 year 8 months ago

Biophytis annonce sa participation au 15ème Congrès International sur la Fragilité et la Sarcopénie (ICFSR)
Biophytis participera au 15ème Congrès ICFSR pour présenter BIO101 dans la sarcopénie associée à l’obésité. La société de biotechnologie se concentre sur le développement de traitements pour les maladies liées à l'âge

Biophytis Sarcopénie Maladies Liées À L'âge Obésité Congrès ICFSR
REGULATED PRESS RELEASE

published on 02/25/2025 at 07:00, 1 year 8 months ago

Biophytis announces its participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)
Biophytis to participate in ICFSR 15th International Conference on Frailty and Sarcopenia Research, presenting data on BIO101 for obesity-associated sarcopenia. Event in Toulouse, March 12-14

Biophytis Sarcopenia ICFSR BIO101 Obesity
BRIEF

published on 02/11/2025 at 07:05, 1 year 8 months ago

Biophytis annonce ses priorités stratégiques pour 2025

Biophytis Partenariats Stratégie 2025 Sarcopénie Obésité
BRIEF

published on 02/11/2025 at 07:05, 1 year 8 months ago

Biophytis Outlines 2025 Strategic Plans

Strategic Partnerships Biophytis Clinical Development Obesity Treatment Sarcopenia
REGULATED PRESS RELEASE

published on 02/11/2025 at 07:00, 1 year 8 months ago

Biophytis dévoile ses perspectives stratégiques de l’année 2025
Biophytis dévoile ses perspectives stratégiques pour l’année 2025, incluant le lancement de nouveaux programmes cliniques et des collaborations clés dans le domaine des maladies liées à l'âge

Stratégie Biophytis Partenariats Développement Clinique Maladies Liées À L'âge
REGULATED PRESS RELEASE

published on 02/11/2025 at 07:00, 1 year 8 months ago

Biophytis unveils its outlook strategies for 2025
Biophytis unveils its strategic outlook for 2025, focusing on clinical development and commercialization plans for BIO101 (20-Hydroxyecdysone) in obesity and sarcopenia, with key partnerships and agreements

Biophytis Clinical Development BIO101 Obesity Strategic Outlook
BRIEF

published on 01/27/2025 at 07:05, 1 year 9 months ago

Biophytis participe à la conférence Biomed Forum à Paris

Biophytis Biotechnologie Investisseurs BIOMED Forum Santé
BRIEF

published on 01/27/2025 at 07:05, 1 year 9 months ago

Biophytis to Participate in BIOMED FORUM Investor Conference

Biophytis Investor Conference Healthcare Sector Paris BIOMED Forum
REGULATED PRESS RELEASE

published on 01/27/2025 at 07:00, 1 year 9 months ago

Biophytis annonce sa participation à la conférence investisseurs BIOMED FORUM
Biophytis annonce sa participation à la conférence investisseurs BIOMED FORUM, occasion de rencontrer des investisseurs pour présenter les avancées et perspectives 2025

Biophytis Biotechnologie Investisseurs BIOMED Forum Conference
REGULATED PRESS RELEASE

published on 01/27/2025 at 07:00, 1 year 9 months ago

Biophytis announces its participation to the BIOMED FORUM investor conference
Biophytis announces participation in Biomed Forum investor conference to engage with investors and share updates on developments for age-related diseases

Biophytis Investor Conference Healthcare Sector BIOMED Forum Age-related Diseases

Accesswire

Published on 11/06/2026 at 22:15, 2 days 10 hours ago

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 19 hours ago

Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 20 hours ago

Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 20 hours ago

Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 10:00, 2 days 22 hours ago

Mongolia Tax Audit

View all ACCESSWIRE

EQS Group

Published on 11/09/2026 at 08:15, 18 minutes ago

EQS-Adhoc: Airbus SE: Airbus commences multi-year share buyback programme, with launch of the first tranche
Published on 11/09/2026 at 08:05, 28 minutes ago

Onodrim Industries secures $300 million Series A at $1.3 billion valuation to strengthen Europe's defence and industrial foundations
Published on 11/09/2026 at 08:00, 33 minutes ago

Aquis Stock Exchange: Transfer to Apex segment
Published on 11/09/2026 at 08:00, 33 minutes ago

Transaction in Own Shares
Published on 11/09/2026 at 08:00, 33 minutes ago

Custodian Property Income REIT plc: Further momentum with majority share-based acquisition strategy, purchasing an £11.0m property portfolio from eight syndicated investment vehicles

Les Echos

Published on 11/09/2026 at 07:00, 1 hour 33 minutes ago

bioMérieux receives U.S. FDA 510(k) clearance for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens including norovirus
Published on 11/09/2026 at 07:00, 1 hour 33 minutes ago

BIOPHYTIS ANNOUNCES THE OPERATIONAL LAUNCH OF ITS JOINT VENTURE IN CHINA
Published on 11/09/2026 at 07:00, 1 hour 33 minutes ago

Biophytis annonce le démarrage opérationnel de sa co-entreprise en Chine
Published on 11/09/2026 at 07:00, 1 hour 33 minutes ago

bioMérieux obtient l’autorisation 510(k) de la FDA américaine pour les dernières versions des tests BIOFIRE® FILMARRAY® Gastrointestinal Panels afin d’optimiser la détection des pathogènes gastrointestinaux, dont le norovirus
Published on 11/06/2026 at 19:06, 2 days 13 hours ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026

View all LES ECHOS COMFI WIRE